Bluejay Diagnostics, Inc. — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Bluejay Diagnostics announced completion of enrollment in SYMON-II, a pivotal 750-patient multicenter clinical validation study for its Symphony IL-6 rapid diagnostic test for sepsis mortality risk assessment. The study enrolled ahead of schedule and achieved a 17% 28-day mortality event rate, providing what management describes as a robust clinical dataset. Data cleaning and analysis are underway; results are expected to support a planned FDA 510(k) regulatory submission.
Why this rating
Pivotal study completion is material for pre-revenue diagnostic company; de-risks regulatory pathway. Enrollment achieved ahead of plan and adequate event rate support commercialization potential. Relative to $2.6M market cap, this is a critical development.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.